Parkinsons disease (PD) is quite a complex disease. It is influenced by a huge variety of risk factors, but we still don't know the true cause of it. Before the onset of the disease itself, it is preceded by a prodromal phase dominated by NMS. PD is comprised of MS and NMS, and the disease itself covers a much broader neuroanatomical area than previously thought, and it is nowadays known that PD has a much broader clinical picture than it is mentioned in Dr. Parkinson's work. This disease presents a great challenge for both the patient and the medical team. Unfortunately, the basis of diagnostics is still the clinical criteria, imaging methods are of minimal help with differential diagnosis, and we are still waiting on the discovery of the true biomarker of this disease. The therapeutic response of levodopa and other antiparkinsonics reduces with time. Although PD has no cure, but thanks to modern therapy, the life expectancy of patients is very similar to that of a healthy population, and the quality of life of patients is much improved compared to what it was before the antiparkinsonics era. DBS can be considered as another milestone that improves the quality of life of patients with PD, particularly those patients who are in a very advanced stage of the disease.